Wednesday, January 13, 2010
media item: new anti-cancer drug called "COTI-2" TD2 and Critical Outcome Technologies Inc. Develop Novel Anti-Cancer Drug
"....small molecule compound was discovered and developed by COTI of London, Ontario, Canada. This working relationship resulted through the expanded relationship between Canadian companies and the Phoenix-based Translational Genomics Research Institute (TGen). TD2, TGen's Scottsdale-based drug-development subsidiary, will work with COTI to complete the Investigational New Drug (IND) enabling research necessary to gain U.S. Food and Drug Administration approval of clinical trials,perhaps by the end of 2010, and eventually move the drug to market where it can benefit patients.....Researchers hope to demonstrate that this oral pill will be especially beneficial for patients with small- cell lung cancer (SCLC), endometrial cancer and ovarian cancer, but may also help treat those with colorectal and pancreatic cancers."
Surgical Technician Schools » 10 Famous Doctors who Made Medicine What it is Today + more
Beyond the history, at the bottom of the page, there are a number of links which you may find interesting such as:
* 100 Best Blogs for Living Healthy on a Budget
* The Surgery is Over… Now What? 4 Tips for A Successful Rehab
* Top 100 Doctor Bloggers
* 100+ Ways to Spring Clean Your Mind and Body
* The Top 50 Surgeon Bloggers
* What Does a Surgical Technician Do?
full free access: Is no news good news? Inconclusive genetic test results in BRCA1 and BRCA2 from patients and professionals' perspectives
Small study but included view of patients and physician views.
Use of Four Biomarkers to Evaluate the Risk of Breast Cancer Subtypes in the Women's Contraceptive and Reproductive Experiences Study
"Our findings offer evidence of differences in the hormone-related risk factors between triple-negative cancers and other ER/PR/HER2-defined subtypes of breast cancer."
Vandetanib, Designed to Inhibit VEGFR2 and EGFR Signaling, Had No Clinical Activity as Monotherapy for Recurrent Ovarian Cancer and No Detectable Modulation of VEGFR2
"Twelve patients entered the study, and accrual was terminated in the first stage because of lack of response or disease stabilization beyond 6 months."
abstract - Impact of bowel obstruction at the time of initial presentation in women with ovarian cancer.
plus read commentary from gyn/onc
NCI Cancer Bulletin: PARP Inhibitor and Metronomic Chemotherapy for Refractory Cancer - Phase I Study of ABT-888 and Metronomic Cyclophosphamide ....
Name of the Trial:
Phase I Study of ABT-888 and Metronomic Cyclophosphamide in Patients with Refractory Solid Tumors or Lymphoma (NCI-09-C-0048).
For More Information (read the article to see direct links to the information):
See the lists of eligibility criteria and trial contact information or call the NCI Clinical Trials Referral Office at 1-888-NCI-1937. The call is toll free and confidential.
Tuesday, January 12, 2010
full free access : Proteomic effects of hormone therapies - new research in Genome Medicine
"New research by Samir Hanash, Ross Prentice and colleagues, recently published in Genome Medicine, suggests that the different proteomic effects of estrogen-alone and estrogen plus progestin treatments may explain the distinctive clinical effects of each therapy."
UC Academic Health News : Findings: UC Gynecologic Cancer Team Expands Services to Northern Kentuck-Dayton
"His goal is to recruit three additional double board-certified gynecologic oncologists who are qualified to perform both cancer care as well as advanced pelvic surgery. This team will cover a wide range east and west of the I-75 stretch between Northern Kentucky and Dayton."
abstract: Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes
definitions we need to know when reading this abstract:
1) microenvironment: a specific set of physical, biological, and chemical factors immediately surrounding the organism;
2) epigenetic: - something that affects a cell, organ or individual without directly affecting its DNA.
Predicting the Outcome of Cytoreductive Surgery for Advanced Ovarian Cancer
"Conclusions: The rates of optimal cytoreduction vary among surgeons. A universally applicable clinical model that can predict which patients will undergo optimal cytoreduction remains elusive. More research is needed to devise a set of uniform criteria that can be used to predict ovarian cancer resectability among different patient populations."
Cancer Survivorship Research Conference 2010: Recovery and Beyond
June 17-19, 2010
Marriott Wardman Park Hotel
Washington, DC
The Biennial Cancer Survivorship Research Conference, initiated in 2002 by the National Cancer Institute’s Office of Cancer Survivorship and the American Cancer Society’s Behavioral Research Center, brings together investigators, clinicians, and survivors to share and learn about the most up-to-date cancer survivorship research. In 2010, the 5th biennial conference is co-sponsored by the National Cancer Institute, the American Cancer Society, LIVESTRONG, and the Centers for Disease Control and Prevention.
press release: Nektar Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer
"The first stage of the NKTR-102 Phase 2 study showed an overall GCIG response rate of 32% (6/19) in the once every 14 days (q14 day) dose schedule and 35% (7/20) for the once every 21 days (q21 day) dose schedule.
Confirmed objective response rates using RECIST were 21% (4/19) and 22% (4/18) for the q14 day and q21 day dose schedules, respectively.
CA-125 response rates were 31% (5/16) and 38% (6/16), for each dose schedule, respectively.
The Phase 2 study has now completed enrollment with a total of 71 patients. Approximately one-third of the patients in the study remain on NKTR-102 treatment, including a number of patients in the first stage of the study."
abstract: Generational risks for cancers not related to tobacco, screening, or treatment in the United States
"CONCLUSIONS:
Despite declining overall cancer death rates, adults are experiencing increased incidence of cancers that are not associated with tobacco or screening relative to their parents. Future research should examine whether similar patterns are exhibited in other modern nations and should identify population-wide avoidable risks that could account for unexplained increases in these residual cancers."
abstract: Physician factors associated with discussions about end-of-life care
this link is the actual research article and from which the media item was based (abstract/only-pay-per-view)
Second Opinion - Doctors Often Delay Conversations About Death With Terminal Patients - NYTimes.com
this is a good article for everyone, IMHO
Obesity and cancer: Effects on risk, screening and mortality | HemOncToday
My response, assuming it gets posted:
"As a cancer (ovarian) survivour, the value of the research and 'weight' concerns are ever present. However, at this very moment weight issues in cancer are primarily a health issue with many unknowns as it relates to specific implications in specific cancers. I see many websites/programs who arbitrarily have included 'weight' issues as a risk factor. Until the exact mechanisms and results are known, I urge great caution as this adds to significant burdens on patients who at this very moment are fighting to survive. It is not ethically or morally appropriate to add to these burdens for those dying of cancer."
Sandi Pniauskas
Subscribe to:
Posts
(
Atom
)
